{"id":597755,"date":"2022-04-27T17:00:01","date_gmt":"2022-04-27T17:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=597755"},"modified":"2022-04-27T17:00:01","modified_gmt":"2022-04-27T17:00:01","slug":"pericarditis-market-trends-analysis-growth-opportunities-clinical-development-activities-emerging-therapies-key-companies-and-epidemiology-forecast-2032","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pericarditis-market-trends-analysis-growth-opportunities-clinical-development-activities-emerging-therapies-key-companies-and-epidemiology-forecast-2032_597755.html","title":{"rendered":"Pericarditis Market Trends Analysis, Growth Opportunities, Clinical Development Activities, Emerging Therapies, Key Companies, and Epidemiology Forecast 2032"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pericarditis Market Trends Analysis, Growth Opportunities, Clinical Development Activities, Emerging Therapies, Key Companies, and Epidemiology Forecast 2032\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Pericarditis Market Trends Analysis, Growth Opportunities, Clinical Development Activities, Emerging Therapies, Key Companies, and Epidemiology Forecast 2032\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Pericarditis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pericarditis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Pericarditis market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Pericarditis Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/38c44accb49faf8637224de6a9c6e19e.jpg\" alt=\"Pericarditis Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pericarditis: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>The term &ldquo;pericarditis&rdquo; refers to inflammation of the pericardial sac and represents the most common pathological process involving the pericardium. It may be further classified into acute pericarditis, incipient\/subacute pericarditis, chronic pericarditis, and recurrent pericarditis.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>As per the American Academy of Family Physicians, Acute pericarditis, inflammation of the pericardium, is found in approximately <strong>5% of patients<\/strong> admitted to the emergency department for chest pain unrelated to acute myocardial infarction. It occurs most often in men <strong>20&ndash;50 years of age<\/strong>.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary; however, in both effectiveness and side-effect profiles.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Pericarditis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>As quoted in a study by Imazio et al. titled, &ldquo;Evaluation and Treatment of Pericarditis A Systematic Review&rdquo;, tuberculosis is a major cause of pericarditis in developing countries but accounts for less than <strong>5% of cases<\/strong> in developed countries, where idiopathic, presumed viral causes are responsible for <strong>80&ndash;90% of cases<\/strong>.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>&ldquo;2015 ESC Guidelines for the diagnosis and management of pericardial diseases&rdquo; by Adler et al. specified that men ages <strong>16&ndash;65 years<\/strong> were at higher risk for pericarditis than women in the general admitted population, with the highest risk difference among young adults compared with the overall population.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>According to DelveInsight&rsquo;s analysis, males are affected more as compared to females, in the case of Pericarditis.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pericarditis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Pericarditis Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><em><strong>Pericarditis market size<\/strong> is anticipated to increase during the study period owing to the rising incident population of pericarditis in the 7MM. The expected launch of emerging therapies will also fuel the market&nbsp;growth.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Pericarditis market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Pericarditis market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pericarditis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical and current <strong>Pericarditis Epidemiology trends<\/strong> for every seven major countries (7MM)&nbsp; from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pericarditis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Pericarditis market<\/strong> or expected to get launched during the study period. The analysis covers Pericarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Pericarditis Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pericarditis Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Novel treatment options, along with increasing awareness regarding Pericarditis are expected to drive the growth of the&nbsp;Pericarditis therapeutics&nbsp;market.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Prominent players including&nbsp;<strong>Kiniska Pharmaceuticals<\/strong> and others are involved in developing therapies for Recurrent Pericarditis.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Pericarditis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Pericarditis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Pericarditis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Pericarditis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Pericarditis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Pericarditis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pericarditis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Pericarditis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Pericarditis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Pericarditis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Pericarditis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Pericarditis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Pericarditis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Pericarditis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Pericarditis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Pericarditis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pericarditis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysautonomia-autonomic-dysfunction-market\">Dysautonomia (Autonomic Dysfunction) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Dysautonomia (Autonomic Dysfunction) Market is set to evolve in the coming years owing to the rising awareness of the disease, the launch of emerging therapies, and the incremental healthcare spending across the world. Some of the key companies such as <em>Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics,<\/em> among others are diligently working in the Dysautonomia (Autonomic Dysfunction) Market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pericarditis-market-trends-analysis-growth-opportunities-clinical-development-activities-emerging-therapies-key-companies-and-epidemiology-forecast-2032\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pericarditis-market-trends-analysis-growth-opportunities-clinical-development-activities-emerging-therapies-key-companies-and-epidemiology-forecast-2032\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Pericarditis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pericarditis Market size, share, and trends in the seven major market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pericarditis-market-trends-analysis-growth-opportunities-clinical-development-activities-emerging-therapies-key-companies-and-epidemiology-forecast-2032_597755.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,405,417,406],"tags":[],"class_list":["post-597755","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=597755"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597755\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=597755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=597755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=597755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}